About Topelia

Topelia Aust Limited (ABN 36 652 771 670) (Topelia) is a public unlisted biotechnology company focused on developing and commercialising its proprietary Antiviral Triple Therapy (ATT) designated TPL101. Having previously achieved success in commercialising a Triple Therapy for Helicobacter pylori, the principals of Topelia have now turned their attention to the TPL101 triple therapy, initially directed towards COVID-19.

Topelia proposes to offer TPL101 antiviral therapy alongside the current strategies of vaccination and currently approved antivirals for COVID-19. As countries experience persistent coronavirus outbreaks, it is vital to have a variety of safe antiviral medical treatment, particularly with the current levels of vaccine hesitancy and falling interest in existing antiviral therapies on the market.

TPL101 comprises the regulator-approved medications ivermectin and doxycycline which have been prescribed for decades and have demonstrated exceptional safety profiles, along with zinc, in a proprietary fixed dose combination. Containing known and approved APIs means that the development pathway will be more rapid, lower cost and lower risk.

As TPL101 exerts its potent antiviral effect by targeting proteins conserved across a range of viruses, Topelia plans to subsequently explore the efficacy of TPL101 as a therapy for other coronavirus infections including Avian influenza as well as Flaviviridae infections including Dengue, Zika and Yellow Fever.